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The neutralizing antibody response to the protective antigen (PA) component of anthrax toxin elicited by
approved anthrax vaccines is an accepted correlate for vaccine-mediated protection against anthrax. We
reasoned that a human anti-PA monoclonal antibody (MAb) selected on the basis of superior toxin neutral-
ization activity might provide potent protection against anthrax. The fully human MAb (also referred to as
MDX-1303 or Valortim) was chosen from a large panel of anti-PA human MAbs generated using transgenic
mice immunized with recombinant PA solely on the basis of in vitro anthrax toxin neutralization. This MAb
was effective in prophylactic and postsymptomatic treatment of rabbits exposed to aerosolized anthrax spores,
and a single intramuscular injection of 1 mg/kg of body weight fully protected cynomolgus monkeys challenged
with aerosolized anthrax spores. Importantly, MAb 1303 defines a novel neutralizing epitope that requires Fc
receptor engagement for maximal activity. F(ab)2 fragments of MAb 1303, which retain equivalent affinity for
PA, are 10- to 100-fold less potent in neutralizing anthrax toxin in vitro. Addition of Fc receptor-blocking
antibodies also greatly reduced the activity of MAb 1303. Moreover, we found that the neutralizing activity of
mouse, rabbit, and human antisera elicited by PA vaccines was effectively abrogated by blocking Fc receptors.
Selection of an anti-PA MAb by using a functional assay that is a surrogate for protection has resulted in the
identification of a fully human MAb with potent activity in vivo and uncovered a previously unrecognized
mechanism of antibody-mediated toxin neutralization that is important for currently used anthrax vaccines.
The intentional use of Bacillus anthracis, the causative agent
for anthrax, as a bioterrorism or biowarfare agent constitutes a
significant health and economic concern. Vaccines for prophy-
laxis against anthrax have been developed and have been ad-
ministered to thousands of people, primarily to members of the
armed forces (8, 9). Anthrax vaccines are highly effective (5),
but because the current licensure for AVA Biothrax requires a
multiple-dose schedule, antibiotic therapy may be recom-
mended for postexposure prophylaxis prior to the completion
of the vaccination series.
Efficacy of the approved anthrax vaccine, AVA Biothrax
(Bioport Corp., Lansing, MI) or the next generation vaccine
based upon recombinant protective antigen (PA) correlates
with the development of humoral responses to the PA com-
ponent of the anthrax toxin (12, 21, 23, 27, 28). During infec-
tion, PA (PA83) binds to cell surface receptors and is cleaved
by a membrane-bound protease, resulting in a receptor-bound
truncated form of PA, PA63, that can oligomerize on the cell
surface into a heptameric structure (7). This ring structure
forms a high-affinity binding site for the bacterial enzymes
lethal factor (LF) and edema factor to form holotoxins that are
translocated into the host cell cytoplasm, where they mediate
their toxic effects.
The correlation of humoral immunity to PA with protection
against anthrax has spawned a number of approaches for de-
veloping passive antibody therapies directed at PA. Studies
have clearly demonstrated the protection elicited by transfer of
sera from PA-immunized animals, and antibody-mediated
toxin neutralization appears to be the best in vitro correlate for
in vivo potency (11, 23). Neutralizing antibody titers are gen-
erally determined using the toxin neutralization assay (TNA),
which measures the inhibition of toxin-mediated cell death of
susceptible murine macrophage-like cell lines. In the absence
of the ability to challenge human subjects, potency of antisera
in a standardized TNA has become an accepted surrogate for
determining the efficacy of various candidate vaccines.
The multiple steps in the pathway of PA binding, processing,
oligomerization, formation of holotoxin, and internalization
are each potential therapeutic targets using a monoclonal an-
tibody (MAb). Initial studies on the characterization of anti-PA
MAbs suggested that MAbs with potent toxin neutralizing ac-
tivity functioned by inhibiting PA-receptor interactions or PA
interactions with LF or edema factor (13, 15). Subsequently,
toxin-neutralizing antibodies have been described that appear
to function by inhibiting the cleavage of cell-bound PA to
PA63 or assembly of the PA63 heptamer (6, 26). Some MAbs
that act by these mechanisms have been shown to protect
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against lethal challenge with aerosolized spores in animals (18,
20) and support the expectation that passive immunity may be
conferred with appropriate single anti-PA MAbs to individuals
exposed to B. anthracis. The relative in vivo efficacy of anti-
bodies that function by each of these mechanisms has not been
established. Moreover, the importance of each of these mech-
anisms to the immunity provided by anthrax vaccines is un-
known.
In this study, we used an unbiased approach with respect to
the precise mechanism for selecting an anti-PA MAb with
superior anthrax toxin-neutralizing activity and chose perfor-
mance in the TNA as the primary criterion. We reasoned that,
since the TNA provides the best in vitro correlate for protec-
tive potency of polyclonal antisera, that it might also provide a
useful approach for identifying potent MAbs and provide ad-
ditional insights into the basis for in vivo protection by the
polyclonal response to vaccines. To generate a MAb with op-
timum characteristics for human application, we developed
fully human MAbs specific for PA by immunization of mice
engineered to express human immunoglobulin in response to
vaccination. The anti-PA human MAb selected on the basis of
superior TNA activity is indeed highly potent in animal models
of anthrax infection. This MAb, designated 1303 or Valortim,
does not block attachment of PA to the cell surface, and full in
vitro protective activity is dependent upon interaction with
host cell immunoglobulin (Fc) receptors. Furthermore, we
found that this Fc receptor dependence is a dominant feature
of the effective polyclonal immune response elicited in humans
and animals by PA-based anthrax vaccines.
MATERIALS AND METHODS
Cell lines and reagents. Anti-PA human reference serum AVR801 was
generously supplied by Conrad P. Quinn, Centers for Disease Control and
Prevention, Atlanta, GA (24). The mouse macrophage cell line J774A.1 was
obtained from the American Type Culture Collection, Manassas, VA. B.
anthracis recombinant LF and PA were obtained from List Biological Labo-
ratories (Campbell, CA).
Immunization of transgenic mice and development of hybridomas. Transgenic
mice from HuMab Mouse colony (17), strain HC2/KCo7, were immunized
intraperitoneally with 15 g of purified recombinant PA (83 kDa) in RIBI MPL
plus TDM adjuvant system and boosted with 15 g of proteolytically cleaved (63
kDa) PA twice at 2-week intervals. A final immunization with 10 g of purified
PA63 was given intravenously (i.v.). Additional mice were immunized using
purified recombinant PA emulsified in Freund’s adjuvant. Three to four days
after the final boost, the spleens were harvested and the splenocytes fused with
the P3x63Ag8-653 myeloma cells using polyethylene glycol. After fusion, the cells
were plated in 96-well plates, and hypoxanthine-aminopterin-thymidine was
added to the media for selection of the hybridomas. Cells which grew out of the
selection media were screened for immunoglobulin G() [IgG()] production by
enzyme-linked immunosorbent assay (ELISA), followed by neutralization activ-
ity utilizing the in vitro TNA. Antibodies were purified from the hybridoma
supernatant using protein A affinity chromatography.
Production and purification of recombinant 1303. The 1303 variable light
chain and variable heavy chain sequences were obtained by reverse transcription-
PCR using RNA extracted from the 1303 hybridoma. The variable light chain
and variable heavy chain sequences were then cloned into a mammalian expres-
sion vector into which the human Ig() and IgG1 genes had been previously
introduced. The fidelity of all cloning steps was verified by DNA sequencing of
the entire 1303 heavy chain and light chain coding regions. The heavy chain and
light chain sequences were cloned into a single mammalian expression plasmid
(p1303) under the control of cytomegalovirus (CMV) promoters and including
the neomycin resistance gene for selection.
For expression and purification of the recombinant MAb 1303, the construct
was transfected into CHO cells using SuperFect reagent according to the man-
ufacturer’s instructions (QIAGEN, Valencia, CA). Stable transfectants were
selected by maintaining cells in growth media ( minimal essential medium, 10%
dialyzed fetal bovine serum) containing 550 M G418 (Calbiochem-Novabio-
chem, San Diego, CA). Subsequently, colonies were isolated using cloning cyl-
inders, and cell lines that produced the highest amounts of MAb were identified
by ELISA. MAb was purified from overgrown culture supernatants using a
protein A-Sepharose column.
TNA. An in vitro neutralization assay described previously was modified and
used to assess the ability of the MAbs to neutralize anthrax lethal toxin (14). The
mouse macrophage cell line J774A.1 was maintained in Dulbecco’s modified
Eagle medium containing glucose, sodium pyruvate, and GlutaMax and supple-
mented with 10% heat-inactivated fetal bovine serum. Cells were scraped from
confluent flasks and suspended to 6  105 to 7  105/ml in the media mentioned
above, plated in 96-well flat-bottom plates (150 l per well), and incubated
overnight at 37°C in a 5% CO2 humidified incubator. Macrophage serum-free
medium containing antibody was preincubated with lethal toxin (400 ng of PA
per ml plus 40 ng of LF per ml) for 1 h at 37°C prior to transferring 100 l to
J774A.1 cells. The plates were incubated for 3 h at 37°C, 5% CO2. To assess cell
viability, 100 l of CellTiter-Glo reagent (Promega Corp., Madison, WI) was
added to each well after the plate was equilibrated to room temperature for 30
min. The plates were mixed on a plate shaker for 2 min to facilitate cell lysis, and
after 10 min, the luminescence signal was recorded on a Wallac 1450 MicroBeta
JET liquid scintillation and luminescence counter. Cell viability was calculated
from the following formula: (mean luminescence counts per second in sample/
mean luminescence counts per second in cells without toxin)  100%. Experi-
ments to investigate the role of Fc receptor interaction were performed as
described, except that rat anti-mouse CD16/CD32 Fc receptor blocking clone
2.4G2 (BD Pharmingen, San Jose, CA) at 100 g/ml was preincubated with
J774A.1 cells for 15 min prior to the addition of anti-PA MAbs and lethal toxin
samples.
Cytokine stimulation assay. Human peripheral blood mononuclear cells
(PBMCs) were purified from fresh whole blood by density gradient centrifuga-
tion and used for cytokine stimulation experiments as described by Popov et al.
(22). Briefly, PBMCs were adjusted to 5  106/ml in RPMI containing 10% fetal
bovine serum. PBMCs (1  106) were incubated overnight at 37°C, 5% CO2 with
10 g/ml lipopolysaccharide (LPS), 0.5 g/ml PA, and 0.5 g/ml LF. MAbs and
F(ab)2 fragments at multiple dilutions were also added to the cultures. The next
day, the supernatants were harvested and assayed for the presence of human
interleukin-6 (IL-6) using an ELISA kit (Pierce, Rockford, IL).
Protection against inhalational anthrax. Rabbit and nonhuman primate
(NHP) models of inhalational anthrax were conducted at Battelle Medical Re-
search and Evaluation Facility, West Jefferson, Ohio, in compliance with the
Animal Welfare Act. New Zealand White rabbits (10/group) were injected i.v.
with MAb 1303 at 1, 24, or 48 h post-muzzle-only aerosol challenge with 100
50% lethal dose (LD50) of B. anthracis strain Ames spores. Cynomolgus monkeys
(6/group) were injected intramuscularly (i.m.) with MAb 1303 at 1 h post-head-
only aerosol challenge with 200 LD50 of B. anthracis strain Ames spores.
Aqueous suspensions of B. anthracis spores were aerosolized by a collision
nebulizer. Inhaled doses were calculated using the concentration of B. anthracis
spores in the test aerosol from the plate counts of the impinger and individual
plethysmography data. Rabbits were observed for 14 days postexposure, and
cynomolgus monkeys were observed for 90 days postexposure. Blood was drawn
periodically during the study for evaluation of serum levels of MAb 1303, anti-
toxin antibodies, bacteremia, and clinical pathology.
Immunoassays for MAb binding to PA. ELISA microtiter plates were coated
with 5 g/ml mouse anti-PA MAb clone BAP 0105 (Biodesign, Saco, ME). After
blocking with phosphate-buffered saline (PBS) containing 5% bovine serum
albumin (BSA), full-length (83 kDa) or cleaved (63 kDa) PA (5 g/ml) was
captured to the plates. Unbound PA was removed, and test samples were incu-
bated on the plate for 1 h at 37°C. Unbound antibody was washed from the plate
with PBS containing 1% Tween, and the wells were incubated with an alkaline-
phosphatase-conjugated goat anti-human IgG (Fc specific) for 1 h at 37°C. The
excess conjugated antibody was washed from the wells, and the plate was devel-
oped with pNPP substrate (Pierce, Rockford, IL). The optical density was de-
termined at 405 nm using a Molecular Devices SPECTRAmax PLUS384 plate
reader.
Western blotting was performed on full-length PA (PA83) and PA fragments
generated by trypsin and chymotrypsin digestion after immunoprecipitation with
MAb 1303 or isotype control MAb. Mabs were bound to protein A agarose beads
(Roche Diagnostics, Indianapolis, IN) for 1 h at room temperature on a tube
rotator. The resin was washed with a buffer containing 50 mM Tris-HCl, 150 mM
NaCl, 1 mM EDTA, 0.1% NP-40, 0.25% gelatin, and 0.02% NaN3, pH 7.5, to
remove unbound MAb before incubating with the PA preparations for 1 h at
room temperature on a tube rotator. The beads were washed with the buffer
described above, and the pellet was resuspended in reducing sodium dodecyl
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sulfate-polyacrylamide gel electrophoresis sample buffer and boiled for 2 min.
The proteins were separated by sodium dodecyl sulfate-polyacrylamide gel elec-
trophoresis on a 12.5% Tris–HCl gel (Bio-Rad Laboratories, Hercules, CA) and
transferred to an immunoblot polyvinylidene difluoride membrane (Bio-Rad
Laboratories, Hercules, CA). The membrane was blocked with SuperBlock
blocking buffer in PBS (Pierce, Rockford, IL), and the PA fragments were
detected with polyclonal rabbit anti-PA IgG at 1 g/ml, followed by an incuba-
tion with a goat anti-rabbit IgG (Fc specific) alkaline phosphatase conjugate
(Jackson ImmunoResearch, West Grove, PA) at a 1:10,000 dilution. The reactive
bands were detected with CDP-Star chemiluminescence substrate (Roche Diag-
nostics, Indianapolis, IN).
Inhibition of PA binding to cells. Anti-PA MAbs (400 g/ml) or human
anti-PA immune sera (diluted 1:2) were incubated for 20 min at room temper-
ature with fluorescein (FITC)-labeled PA83 (PA-FITC) at 40 g/ml in PBS
containing 0.1% BSA and 0.05% sodium azide. This solution was then added to
human PBMCs and incubated for an additional 1 h at room temperature on a
plate shaker. Samples were washed twice with PBS containing 0.1% BSA and
0.05% sodium azide to remove unbound antibody and then read immediately on
a Becton Dickinson LSR flow cytometer to determine the level of fluorescence
of the PA-FITC bound to the monocyte population.
RESULTS
Human anti-PA MAbs selected for potent toxin-neutralizing
activity. The HuMAb mouse was engineered to express human
rather than murine Ig and has been successfully used to gen-
erate human MAbs to a variety of antigens. Human MAbs
derived from these mice are in a variety of clinical trials, have
demonstrated low immunogenicity, and persist in circulation
for an extended time in humans (16). To generate human
MAbs to PA, HuMAb mice were immunized with recombinant
PA and the spleen cells were fused with myeloma cells. Hy-
bridomas were initially selected on the basis of human IgG()
secretion by ELISA. Supernatants from all of the stable human
IgG()-secreting hybridomas were then evaluated for toxin
neutralization activity in vitro. Screening of hybridomas from 7
different fusions yielded more than 100 clones with neutraliz-
ing activity. A wide range of activity was observed (50% effec-
tive dose, 1 to 100 nM). One MAb, designated MAb 1303,
consistently had the lowest 50% effective dose values and com-
pared favorably to the previously characterized murine anti-PA
MAbs (Fig. 1). MAb 1303, generated from immunization con-
taining both PA63 and PA83 and selected solely on potency in
the neutralization assay, was further developed for testing in
animal models of inhalational anthrax.
MAb 1303 protects against inhalational anthrax. The pro-
phylactic activity of MAb 1303 was evaluated in a rabbit inha-
lational model of anthrax infection. The initial study using
MAb 1303 purified from supernatants of the hybridoma cul-
ture demonstrated significant protection from an aerosol chal-
lenge of anthrax spores (average dose, 200 LD50). Nine of 10
animals receiving a total dose of 17 mg/kg of body weight
survived, and 8 of 10 animals receiving 9 mg/kg survived. All 10
animals in the saline control group died within 5 days. The
MAb 1303 was subsequently engineered into a human IgG
FIG. 1. Neutralization of lethal toxin activity by anti-PA MAbs.
Various concentrations of purified human (1303) and murine (1G3,
14B7) MAbs were premixed with anthrax lethal toxin (400 ng PA and
40 ng LF per ml) before addition to J774A.1 macrophages. Viability
was determined after 3 h of incubation. Values represent the means of
results from duplicate wells of a representative experiment.
FIG. 2. Efficacy of MAb 1303 in animal models of inhalation anthrax. Various doses of MAb 1303 were administered to rabbits (A) or
cynomolgus monkeys (B) following aerosol challenge with B. anthracis Ames spores. (A) Results are from 2 studies consisting of groups of 10
rabbits injected i.v. with MAb 1303 at the indicated times. (B) Groups of 6 monkeys were injected i.m. with MAb 1303 approximately 1 h after
aerosol challenge. The challenge dose ranged from 100 to 300 LD50 in these studies. d, day.
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expression vector and produced from transfected CHO cells
for higher productivity. In a second efficacy study, lower doses
of MAb 1303 were used and found to be equally effective in
protecting rabbits against inhalational anthrax (Fig. 2A). The
lowest dose tested (1 mg/kg) injected 1 h and 3 days post-
anthrax exposure was sufficient to protect 9 of 10 animals.
Surviving animals were free of pathology or other evidence of
infection at 14 days postexposure.
The activity of MAb 1303 against inhalational anthrax was
confirmed in an animal model using cynomolgus macaques.
Animals were challenged with anthrax spores (200 LD50) and
injected i.m. with a single dose of 1 mg/kg or 10 mg/kg of MAb
1303 1 h post-anthrax exposure. Both dose levels resulted in
complete protection from severe clinical symptoms and death
for the duration of the 90-day observation period (Fig. 2B).
Pharmacokinetic analysis of MAb 1303 in macaques suggests
that serum concentrations between 3 to 10 g/ml during the
first 2 weeks of exposure were sufficient to mediate protective
immunity (data not shown).
Therapeutic activity of MAb 1303 against inhalational an-
thrax. In addition to prophylaxis, the antitoxin activity of anti-PA
MAbs may be therapeutically useful after symptoms have
emerged. To model this, MAb 1303 was administered to rabbits
24 or 48 h after aerosol exposure to B. anthracis spores. At 24 h
postexposure, the animals were not overtly symptomatic; how-
ever, 1 of 10 animals had slightly elevated serum enzyme levels
and all animals had significant decreases in peripheral blood neu-
trophil counts. Eight of the nine animals treated at 24 h survived
the infection; therefore, no decrease in the antibody’s efficacy was
noted compared to prophylactic treatment.
In the 48-h-postexposure group, 3 of 10 animals died prior to
receiving the MAb. Three of the seven animals treated with MAb
at 48 h died within 24 h of the first treatment (2 to 3 days
post-exposure to anthrax), and one animal died 3 days after treat-
ment (5 days postexposure). The remaining three animals sur-
vived until study termination (43% survival). Clinical signs of
anthrax infection were apparent at the time of treatment in six of
the seven animals. Four of these animals exhibited decreased
appetite, and two animals had decreased activity at 48 h post
exposure. In addition, elevated serum enzyme levels were appar-
ent in five of the seven animals. In two of these animals, alanine
transaminase levels were dramatically increased (1,500 U/liter),
indicating that significant hepatoxicity was present prior to MAb
1303 administration, and these two animals died within 24 h of
treatment. One of the three surviving animals also had elevated
aspartate transaminase and alanine transaminase levels at the
time of administration of the MAb. Combined, these data indi-
cate that treatment with MAb 1303 can decrease mortality rates
in overtly symptomatic animals as well as in animals that show
laboratory signs consistent with infection. Thus, the premise of
selecting an anti-PA MAb based on superiority in the in vitro
toxin neutralization assay indeed resulted in a highly effective
MAb against inhalational anthrax.
Functional characterization of MAb 1303. The specificity
and mechanism of action of MAb 1303 was further investigated
using in vitro experiments. MAb 1303 recognized both full-
length PA (PA83) and PA63 by ELISA (Fig. 3). Immunopre-
cipitation of PA83 and its cleavage products obtained by tryp-
sin and/or chymotrypsin treatment further identified the PA47
fragment to contain the MAb 1303 epitope (Fig. 3c). This
fragment is largely composed of domain IV of PA and includes
the receptor binding region. However, MAb 1303 does not
competitively bind the epitope of MAb 14B7 (data not shown)
that blocks receptor binding, 14B7 (15), and is unable to block
FITC-labeled PA from binding to cells (Fig. 4, top). In addi-
tion, as receptor-blocking antibodies can also neutralize in
vitro preformed lethal toxin (PA-63)7 plus LF by preventing
FIG. 3. Binding of MAb 1303 to PA. MAb 1303 was tested for
binding to PA83 (A) and PA63 (B) by ELISA. Recombinant PA was
captured to microtiter plates with murine MAb and exposed to various
concentrations of MAb 1303 or isotype control antibody. MAb binding
was detected with an anti-human IgG-specific probe. PA83 was sub-
jected to trypsin (T) and/or chymotrypsin (C) digestion followed by
immunoprecipitation with MAb 1303 or isotype control IgG (C). PA
and PA fragments were visualized by Western blotting with a rabbit
anti-PA polyclonal antibody probe. OD, optical density.
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binding to cells, MAb 1303 is unable to neutralize in vitro
preformed lethal toxin complexes (Fig. 5). Thus, MAb 1303
represents an antibody with specificity for the carboxy-terminal
region of PA that does not interfere with receptor binding or
LF-PA interactions but neutralizes lethal toxin cytotoxicity and
infection with B. anthracis spores.
These results suggested that the in vitro neutralization activity
of MAb 1303 was mediated by interference with toxin assembly at
the cell surface. In fact, antibodies that block the proteolytic
processing or heptamerization of PA have been recently de-
scribed (6, 26). We hypothesized that the function of MAb 1303
should be retained by the F(ab)2 fragment of the antibody. Sur-
prisingly, removal of the Fc portion of MAb 1303 resulted in a
nearly 2-log reduction in activity (Fig. 6). Moreover, addition of
an anti-Fc receptor MAb that blocks Ig binding (25), similarly
reduced the neutralizing capacity of the MAb 1303, indepen-
dently demonstrating the requirement of Fc receptor interactions
for the full potency of MAb 1303 (Fig. 6). The anti-Fc receptor
antibody had no effect on the neutralizing activity of the receptor-
blocking MAb 14B7 (data not shown).
To explore whether the observation of Fc receptor depen-
dence was a characteristic of the particular cellular TNA em-
FIG. 4. MAb 1303 does not block PA binding to cells. Flow cytometry
of PA-FITC binding to human monocytes in the presence or absence of
anti-PA antibodies was analyzed. Anti-PA antibodies (14B7, 10 g/ml;
1303, 10 g/ml; AVR801, 1:100) were preincubated with PA-FITC for 20
min prior to incubation with monocytes for 1 h at ambient temperature.
After washing, the cell-associated fluorescence was determined. The
shaded histogram represents cells not exposed to PA-FITC.
FIG. 5. Lethal toxin formed in vitro is not neutralized by MAb 1303. The standard TNA was performed with either PA83 or PA63 (heptamer)
and lethal factor preincubated with various concentrations of MAb 1303 (A) or MAb 14B7 (B). Viability of the cells was determined after 3 h.
Values represent the means of results from duplicate wells of a representative experiment.
FIG. 6. Fc receptors cooperate in the toxin neutralization activity
by MAb 1303. The TNA activities of MAb 1303, MAb 1303 F(ab)2
fragments, and MAb 1303 in the presence of an Fc receptor-blocking
antibody (2.4G2, 20 g/ml) were determined using J774A.1 cells. Val-
ues represent the means of results from duplicate wells of a represen-
tative experiment. -Fc	RII/III, anti-Fc	RII/III.
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ployed in these experiments, we examined the activity of MAb
1303 and MAb 1303 F(ab)2 in another relevant assay for
anthrax toxin-mediated toxicity. We adapted an assay de-
scribed by Popov et al., who measured suppression of cytokine
secretion by human PBMC stimulated by LPS in the presence
of anthrax lethal toxin (22). In these assays, MAb 1303 was
again much more potent than F(ab)2 fragments of MAb 1303
in restoring the ability of the human PBMC to produce inflam-
matory cytokines (IL-6) in response to LPS (Fig. 7). Similar
effects were observed with isolated cultured human monocytes
or dendritic cells (data not shown). These data demonstrate
that the Fc receptor-dependent mechanism of toxin neutral-
ization by MAb 1303 is applicable to multiple relevant assay
systems for anthrax toxin-mediated toxicity.
Fc receptor-dependent neutralization activity of anthrax
vaccine-induced antibodies. An Fc receptor-dependent toxin
neutralization activity had not been previously described, and
thus, we investigated whether this characteristic was true of
antibodies that are generated in response to protective anthrax
vaccines. AVR801 is a CDC human reference antiserum pre-
pared from pooled antisera of AVA-immunized individuals
and contains 109.4 mg/ml anti-PA IgG (24). The TNA activity
of AVR801 was effectively abrogated by the addition of the
blocking anti-Fc receptor MAb (Fig. 8b). Similar results were
observed with immune serum collected from mice and rabbits
vaccinated with recombinant PA83 (Fig. 8a). These data sug-
gest that Fc receptor-dependent neutralization is a common
characteristic of polyclonal antibodies generated by PA-con-
taining anthrax vaccines. Interestingly, under the conditions of
our experiments, AVR801 was also unable to interfere with PA
binding to cells (Fig. 4, lower panel). This suggests that an
alternative mechanism to blocking of PA binding to cell recep-
tors, which is dependent on Fc receptors, is important for the
toxin neutralizing activity of immune sera.
DISCUSSION
In this study, we used the cell-based anthrax toxin neutral-
ization assay as the sole method to select a human anti-PA
MAb with potential clinical utility, as opposed to other ap-
proaches based on antibody affinity or inhibition of receptor
binding. As predicted from previous studies correlating potent
toxin neutralization activity with protection in animals, MAb
FIG. 7. MAb 1303 abrogates anthrax toxin-mediated inhibition of
cytokine induction in human cells. Human PBMCs were exposed to
LPS (1 g/ml) in the presence of lethal toxin with or without anti-PA
antibodies. The level of IL-6 in culture supernatant after overnight
incubation was determined by ELISA. Values represent the means of
results from duplicate wells of a representative experiment.
FIG. 8. Neutralizing activities of animal and human immune sera are dependent on Fc receptor interactions. The TNA activities of immune
sera from mice or rabbits immunized with recombinant PA vaccine were assessed in the presence or absence of an Fc receptor-blocking antibody,
2.4G2 (A). Similarly, the human reference serum (AVR-801) was tested for TNA activity with or without MAb 2.4G2 (100 g/ml) (B). Values
represent the means of results from duplicate wells of a representative experiment. -PA, anti-PA.
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1303 was effective in the prevention of anthrax lethality in
rabbits and NHPs despite the aerosolized administration of
greater than 100 times the lethal dose of virulent spores. To
our knowledge, the lowest dose tested of MAb 1303 (1 mg/kg)
is the lowest dose of an anti-PA MAb to show 100% protection
in the NHP model. Our unexpected observation was the Fc
receptor dependence of toxin neutralization for this anti-PA
antibody.
Unlike previously described anti-PA MAbs, MAb 1303 ac-
tivity was only partially mediated by the direct attachment of
the antibody binding domains. Experiments using MAb 1303
F(ab)2 fragments and Fc receptor-blocking antibodies, in two
different assay systems, definitively demonstrated the require-
ment for Fc receptor binding by the Fc domain of MAb 1303
for full toxin-neutralizing potency. In the absence of Fc recep-
tor interaction, MAb 1303 was 1 to 2 logs less effective than
under conditions that promote Fc receptor interactions. Our
results may suggest that immune complexes consisting of cell-
bound PA, MAb 1303, and Fc receptors are formed at the cell
surface, resulting in interference with the subsequent oli-
gomerization of PA into viable toxin complexes and their
translocation. Consistent with this hypothesis, MAb 1303 failed
to neutralize preformed toxin complexes but could significantly
prevent cell death up to 20 min after the addition of PA and LF
subunits to J774 cells (data not shown).
Although an Fc receptor dependence of anthrax toxin neu-
tralization was not demonstrated with prior antibodies, we
examined whether this feature was unique to MAb 1303. In-
terestingly, a similar Fc-dependent characteristic was found
with the second most potent human MAb generated in our
studies as well as with the well-characterized, neutralizing
anti-PA MAb 1G3 (data not shown) (15). Furthermore, we
demonstrated that the toxin-neutralizing activity of (pooled)
human and animal polyclonal immune sera was also substan-
tially abrogated in the presence of an anti-Fc receptor MAb. Fc
receptor blockade had no inhibitory effect on the toxin neu-
tralization of an anti-PA MAb that functions by blocking PA
binding to cell receptors, consistent with the expectation that
such activity would only be active on circulating PA, not after
binding to the cell surface. Consistent with the TNA results, we
were unable to demonstrate that the polyclonal immune sera
contained significant blocking activity for PA binding to cell
receptors, suggesting that the natural predominant mechanism
of anthrax toxin neutralization by antibodies elicited by an-
thrax vaccines do not function by inhibiting initial PA binding
but via other epitopes that permit an Fc receptor-mediated
interaction on the cell surface.
The precise mechanism by which Fc receptor interaction
with anti-PA MAbs results in enhanced activity remains to be
established. MAb binding to receptor-bound PA and Fc recep-
tors may result in immune complex formation at the cell sur-
face that are endocytosed into degradation pathways mediated
by the Fc receptor, or simply interfere with the proper toxin
assembly. Recent studies by Abrami et al. demonstrated that
the cellular internalization of the anthrax toxin involves a rel-
atively slow clustering of the anthrax toxin receptor (ATR) into
lipid rafts (2). The investigators also showed that palmitoyl-
ation prevents ATR from association with lipid rafts and pre-
mature internalization (1), and only heptameric PA63 (not
monomeric PA83) can cluster the ATR into lipid rafts. Thus,
endocytosis of the ATR-bound monomeric PA remains slow
until the processing and oligomerization of PA63 occurs. Pre-
sumably, this would allow time for MAb 1303 to bind ATR-
PA83 and ATR-PA63 (before heptamerization) complexes
and simultaneously engage Fc receptors with the Fc portion of
the MAb. Such interactions may result in premature internal-
ization of the ATR-PA complex or prevent the appropriate
migration to lipid rafts for toxin assembly and endocytosis. The
fact that the in vitro toxin neutralization assay requires signif-
icantly less MAb 1303 than PA83 (Fig. 1) suggests that one
molecule of 1303 may be interacting with multiple PA mole-
cules or that a single immune complex may be sufficient to
interfere with heptamer formation/function. We are currently
investigating how these mechanisms may be contributing to the
neutralizing effect of MAb 1303 and other anti-PA antibodies.
Interestingly, Mohamed et al. found that certain anti-PA
MAbs could enhance the cytotoxicity mediated by lethal toxin
in an Fc receptor-dependent manner (19). Since our selection
was for antibodies that mediate potent neutralization of lethal
toxin, it is unknown whether human MAbs may also mediate
the enhancing effect described with some murine anti-PA
MAbs. Alternatively, it may be the epitope specificity that
determines the nature of the Fc receptor interaction and its
outcome on toxin activity.
The absolute relevance of the Fc receptor interaction to the
in vivo efficacy of anti-PA antibodies remains to be understood.
MAb 1303 does protect against anthrax toxin cytotoxicity in the
absence of Fc receptor interactions (albeit at significantly
higher concentrations); thus, in vivo protection cannot be un-
ambiguously attributed to the Fc-enhanced neutralization ac-
tivity. Although some cells that are targets for the anthrax toxin
in vivo do not express Fc receptors, many cells of the immune
system which are critical to the innate response to pathogens
have abundant expression of Fc receptors. In particular, den-
dritic cells have been implicated as a critical cell in the initial
response to B. anthracis infection (3, 4). Therefore, it is rea-
sonable to consider the Fc receptor interactions of anti-PA
MAbs to be important to their efficacy in vivo.
In addition to defining a novel mechanism of action for
anti-PA antibodies, our studies with delayed administration of
MAb 1303 to infected and symptomatic animals suggests this
MAb may be effective in a therapeutic setting. Since antibiotics
have limited efficacy after exposure, development of additional
therapeutic options for symptomatic individuals is of high im-
portance. A recent report has suggested that passive immunity
can be effectively combined with antibiotics resulting in greater
therapeutic efficacy (10, 20). Therapeutic modeling in animals
is challenging with anthrax because of the lack of consistent
clinical symptoms prior to death, which makes it difficult to
separate postexposure prophylaxis from therapeutic interven-
tion. Further studies with this novel antibody in a therapeutic
setting, alone and in combination with antibiotics, will be im-
portant to establish the utility of this MAb in the defense
against anthrax.
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